News and Announcements
Plant-Based Nanotechnology Company Empowers the Next Frontier in Human Wellness
- Published July 22, 2021 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
“Everything you need for great health is in plants, not chemicals. However, plant compounds with the most healing power aren’t soluble in water, and if they don’t dissolve into water, they won’t dissolve into you.
Providing highly potent extracts that the body can easily absorb is something ordinary health products don’t do. You won’t get all the benefits that are there.
We have cracked the code through science and can deliver these difficult to absorb healing compounds to the body as water-soluble nanoparticles that are hundreds of times smaller than red blood cells, making them easy to absorb.”
Phillip Ferguson, Co-Founder & CEO, Nano Nutrients
Executive Summary
Nano Nutrients is an Australian health technology company specialising in chemical-free plant-based nanoparticle and water-soluble technologies for its brand of consumer products.
It has developed world-first technology that shrinks botanical and natural compounds (including one of the most researched plant healing compounds of all time), making them easy to absorb into the body.
Investment Highlights
- Nanotechnology is the next frontier in human wellness and is set to disrupt the global supplements industry.
- Nano Nutrients currently has 12 products in its portfolio, with more under development. Its CleanCurcumin™ proprietary technology is under provisional patents in the US and Australia. Over 10,000 studies show that Curcumin can potentially prevent or treat neurological, cardiovascular, and gastrointestinal disorders.
- The company’s founding team and board members are all experienced in business, plant science, logistics, e-commerce, distribution, health supplements, pharmaceutical/nutraceutical formulation, and medicine.
- The global nutraceuticals market will grow at 7.5% CAGR from USD 241B in 2019 to USD 373B in 2025.
- Nano Nutrients has a vertically integrated agreement with a leading FDA and GMP-certified cannabinoid extraction, nutraceutical, laboratory, and manufacturing company.
Investment Offering
Nano Nutrients is currently raising $1M to commercialise its recently developed portfolio of products. Investors could be eligible for ESIC status.
Company Updates
The System’s Immune System: Why Big Tech Will Solve What Big Pharma Can’t
The central investment thesis for the future of human health pits Big Pharma against Big Tech. This blog post explores the “Protocol Paradox” in current cancer care and argues that the convergence of hyperscalers and life-science experts—treating biology as a data and compute problem—represents the defining compounding investment opportunity of this era.
The Life Sciences Supercycle: Why Australian Biotech is Finally Delivering Billion-Dollar Outcomes
Australia’s life sciences sector is experiencing an unprecedented “Supercycle,” finally commercializing world-class research into global, billion-dollar businesses. Learn about the ASX heavyweights, the key drivers (AI, institutional execution, FDA pathway), and the investment opportunity at Emergence 2026.
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
Backed By Leading Investment Groups and Family Offices
